Tenax Therapeutics Inc(TENX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.47 | Insider Own | 9.48% | Shs Outstand | 37.4M | Perf Week | 15.34% |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | 0.53% | Insider Trans | 103.96% | Shs Float | 33.9M | Perf Month | 2.17% |
| Enterprise Value | -0.05B | PEG | - | EPS next Q | -0.36 | Inst Own | 96.77% | Short Float | 21.34% | Perf Quarter | -87.55% |
| Income | -0.06B | P/S | - | EPS this Y | -8.54% | Inst Trans | 24.5% | Short Ratio | 1.29 | Perf Half Y | -85.29% |
| Sales | 0.00B | P/B | 0.53 | EPS next 5Y | -8.69% | ROA | -57.02% | Short Interest | 7.23M | Perf YTD | -84.58% |
| Book/sh | 3.56 | P/C | 0.6 | EPS past 3/5Y | 86.93% 77.09% | ROE | -59.8% | 52W High | -90.31% ($19.40) | Perf Year | -73.96% |
| Cash/sh | 3.15 | P/FCF | - | Sales past 3/5Y | - | ROIC | -57.1% | 52W Low | 43.51% ($1.31) | Perf 3Y | -90.71% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -59.74% | Gross Margin | - | Volatility(W/M) | 9.12% 7.24% | Perf 5Y | -99.92% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.16 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 15.07 | EPS Q/Q | -27.69% | Profit Margin | - | RSI (14) | 47.95 | Recom | 1.8 |
| Dividend Gr. 3/5Y | - | Current Ratio | 15.07 | Sales Q/Q | - | SMA20 | 8.12% ($1.74) | Beta | 0.99 | Target Price | $9.62 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/7/31 | SMA50 | 1.94% ($1.84) | Rel Volume | 0.3 | Prev Close | $1.72 |
| Employees | 16 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 8.21% - | SMA200 | -81.6% ($10.22) | Avg Volume(3M) | 5.61M | Price | $1.88 |
| IPO | 1994/4/4 | Option/Short | Yes/Yes | Trades | 4101 | Volume | 1,656,168 | Change | 9.3% |
💊 A US clinical-stage biotech company with a core indication of heart failure with preserved ejection fraction (HFpEF) combined with pulmonary hypertension. The company is developing cardiovascular calcium sensitizer candidates from the levosimendan family in both oral and intravenous formulations and has now entered the late-stage clinical phase.
Over the past 1 year, on the lower side
90% below its 1-year high.
Traded less than usual. That is 30% of its average volume.
TENX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -8.5% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
21.3% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #390 of 594 in the industry
Based on market cap of $70M.
MAIA#388 MAIA Biotechnology Inc $72M PER - 
CGTX#389 Cognition Therapeutics Inc $71M PER - TENX#390 Tenax Therapeutics Inc $70M PER - 
CRDF#391 Cardiff Oncology Inc $70M PER - 
CSBR#392 Champions Oncology Inc $68M PER - 
FAQ
What kind of company is TENX?
TENX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TENX?
The market cap of TENX is approximately $70M, ranking 4,690 within its sector.
What is the 52-week high and low for TENX?
TENX has recorded a 52-week high of $19.40 and a low of $1.31.
